What cross-linking does
Corneal collagen cross-linking (CXL) uses riboflavin (vitamin B2) eye drops and controlled ultraviolet-A light to form new chemical bonds between the cornea’s collagen fibres. The effect is a measurable increase in corneal stiffness — the bulge of keratoconus is braced from within.
CXL is the only treatment proven in clinical studies to halt keratoconus progression. It treats the disease process itself, unlike glasses or lenses, which only compensate for its optical effect. It does not aim to remove your spectacle number, and any vision change afterwards is usually gradual and modest.
Who may be a candidate
The classic candidates are patients with documented progression of keratoconus — worsening topography, thinning, or increasing irregular astigmatism over time. Age, corneal thickness, the steepness of the cone and eye health all influence which CXL protocol is appropriate, and some thin corneas need modified approaches. The key step is confirming progression with serial scans, because treating a stable cornea offers little benefit.
The procedure, step by step
Preparation: the eye is numbed with anaesthetic drops. The central epithelium (surface layer) is removed or loosened depending on the protocol — this lets riboflavin reach the stroma.
Soaking: riboflavin drops are applied for a measured period until the cornea is fully saturated.
Illumination: the eye is positioned under a UVA lamp for a set dose, monitored throughout. The patient lies still looking at a target light.
Aftercare: a bandage contact lens is placed and protective drops are prescribed. A patch and review visits follow in the first days and weeks.
The procedure is typically done for one eye at a time. Total theatre time is usually under an hour; the UVA exposure itself is much shorter.
Recovery and what to expect
The first 2–4 days involve foreign-body sensation, watering and light sensitivity while the surface heals — managed with drops and the bandage lens. Most patients return to routine activities within about a week, with gradual surface healing over several weeks. Stabilisation of the cornea’s shape is assessed with repeat topography over the following 6–12 months. Vision may fluctuate during healing; any improvement in shape-related distortion is gradual.
Risks and limitations
CXL is considered safe in trained hands, but no procedure is risk-free. Possible issues include delayed surface healing, infection (rare), temporary haze within the cornea, and in a small proportion of treated eyes, a slight permanent haze. Rarely, thinning can continue. These risks are weighed against the established risk of untreated progression, which in moderate keratoconus is substantial. CXL does not restore lost vision by itself — visual rehabilitation (lenses, or other procedures in selected cases) is a separate, later conversation.